No patients died of prostate cancer. The 5-year overall survival was 90%.

The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Angela Jia discussing the clinical ...

The 2025 ASTRO annual meeting featured a prostate cancer radiation toxicity session and a presentation by Dr. Young Suk Kwon discussing an EPIC-26 longitudinal analyses of prostatic urethral lift ...

The MARCAP Consortium is the largest independent data repository and statistical analysis team, with Dr. Spratt and Dr. Amar Kishan as co-primary investigators. The purpose of the first MARCAP ...

This was a single-center, retrospective analysis of 42 patients with MIBC who underwent TMT at the Moffitt Cancer Center between October 2019 and April 2024 and had ≥1 post-TMT ctDNA (Signatera TM) ...

Stereotactic body radiation therapy (SBRT), defined as the delivery of >5Gy per fraction, has emerged as a well-established standard of care option for the definitive management of localized prostate ...

The PCS5 trial is a Canadian multicenter, open-label, phase III randomized trial that included men with histologically proven, clinically localized prostate cancer with ≥1 high-risk feature (s) ...

At a median follow-up of 19.6 months, the median PSA was 0.028 ng/mL. 18/100 patients developed biochemical recurrence, with a median time to recurrence of 10 months. The biochemical recurrence-free ...

A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a median age of 65 years (IQR 59-71), 50% with positive surgical margins, 51% ...

ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of ...